Contributor since: 2010
Company: Discontinued
Latest Articles
How BioSig Technologies Is Positioned To Change The Electrophysiology Market
Nuvo Research Spin-Out Should Unlock Value For Investors
A Quick Look At BioLineRx
What's Going On With Nuo Therapeutics?
TrovaGene Looks To Revolutionize The Cancer Diagnostic Market
November Options Are Low Risk Way To Play Neurocrine Biosciences' Pending Catalysts
What To Buy Based On The Biotech Pullback
Bellus Health On Track To Report Phase 3 Kiacta Data Mid 2016
NephroGenex Pyridorin Could Be A Blockbuster Drug For Diabetic Nephropathy
Should The New Aralez Pharmaceuticals Be In Your Portfolio?
Why I Think InVivo Shares Are Worth A Double
Nucynta Powers Depomed Past Horizon Bid
Corbus Calls Warrants, Pushes Forward In Three Phase 2 Trials With Resunab
Neuralstem Wins Patent Infringement Case Vs. StemCell, Inc.; Moves Forward In Spinal Cord Injury
Nasdaq-Listed Pieris Offers Enormous Potential
Epirus Signs Profit-Sharing Collaboration With PolPharma Group
MabVax: An Underappreciated Cancer Immunotherapy Play
Pozen And Tribute To Merge, Form New Aralez Pharma Plc
A Deep Look At Depomed's Billion-Dollar Bet On Nucynta
ADMA Biologics Shares Possibly Worth A Triple On FDA Approval Of RI-002
Lipocine Is An Attractive Specialty Pharma Story
Why Newly NASDAQ-Listed Cynapsus Looks Like A Potential Big Winner
Preclinical Data At ADA Supports Development Of AntriaBio's AB101
GenSpera And Cancer-Specific Hand Grenades
Lipocine Gets Orphan Designation For Preterm Birth Drug
Avita Medical: Why This Tiny Medical Device Player Is Positioned For A Turnaround
Matinas' MAT9001 Beats Vascepa In Head-To-Head Trial
Amarantus Sets Sights On NASDAQ
Nuvo's Revamped Strategy Should Unlock Significant Value
Recent News Highlights Pieris's Efforts In Immuno-Oncology
ContraFect Initiates Human Studies With Potential Breakthrough New Antibiotic
Neurotrope Tackling Alzheimer's, Other Orphan Indications